Page 1971 - Williams Hematology ( PDFDrive )

1946 Part XII: Hemostasis and Thrombosis Chapter 113: Molecular Biology and Biochemistry of the Coagulation Factors 1947

240. Beringer DX, Kroon-Batenburg LMJ. The structure of the FnI-EGF-like tandem 273. Rezaie AR, Cooper ST, Church FC, Esmon CT: Protein C inhibitor is a potent inhibitor
domain of coagulation factor XII solved using SIRAS. Acta Crystallogr Sect F Struct Biol of the thrombin-thrombomodulin complex. J Biol Chem 270:25336–25339, 1995.
Cryst Commun 69:94–102, 2013. 274. Martin FA, Murphy RP, Cummins PM: Thrombomodulin and the vascular endothe-
241. Kannemeier C, Shibamiya A, Nakazawa F, et al: Extracellular RNA constitutes a natural lium: Insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart
procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104:6388–6393, Circ Physiol 304:H1585–H1597, 2013.
2007. 275. Ohlin AK, Norlund L, Marlar RA: Thrombomodulin gene variations and thromboem-
242. van der Meijden PE, Munnix IC, Auger JM, et al: Dual role of collagen in factor XII– bolic disease. Thromb Haemost 78:396–400, 1997.
dependent thrombus formation. Blood 114:881–891, 2014. 276. Tang L, Wang HF, Lu X, et al: Common genetic risk factors for venous thrombosis in
243. Muller F, Mutch NJ, Schenk WA, et al: Platelet polyphosphates are proinflammatory the Chinese population. Am J Hum Genet 92:177–187, 2013.
and procoagulant mediators in vivo. Cell 139:1143–1156, 2009. 277. Langdown J, Luddington RJ, Huntington JA, Baglin TP: A hereditary bleeding disor-
244. van der Meijden PE, van Schilfgaarde M, van Oerle R, et al: Platelet- and erythro- der resulting from a premature stop codon in thrombomodulin (p.Cys537Stop). Blood
cyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Hae- 124:1951–1956, 2014.
most 10:1355–1362, 2012. 278. Delvaeye M, Noris M, De Vriese A, et al: Thrombomodulin mutations in atypical
245. Revak SD, Cochrane CG, Bouma BN, Griffin JH: Surface and fluid phase activities of hemolytic-uremic syndrome. N Engl J Med 361:345–357, 2009.
two forms of activated Hageman factor produced during contact activation of plasma. J 279. Fukudome K, Esmon CT: Molecular cloning and expression of murine and bovine
Exp Med 147:719–729, 1978. endothelial cell protein C/activated protein C receptor (EPCR). The structural and
246. Lämmle B, Wuillemin WA, Huber I, et al: Thromboembolism and bleeding tendency functional conservation in human, bovine, and murine EPCR. J Biol Chem 270:5571–
in congenital factor XII deficiency—A study on 74 subjects from 14 Swiss families. 5577, 1995.
Thromb Haemost 65:117–121, 1991. 280. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood
247. Renne T, Pozgajova M, Gruner S, et al: Defective thrombus formation in mice lacking 109:3161–3172, 2007.
coagulation factor XII. J Exp Med 202:271–281, 2005. 281. Mosnier LO, Sinha RK, Burnier L, et al: Biased agonism of protease-activated receptor 1
248. Matafonov A, Leung PY, Gailani AE, et al: Factor XII inhibition reduces thrombus for- by activated protein C caused by noncanonical cleavage at Arg46. Blood 120:5237–5246,
mation in a primate thrombosis model. Blood 123:1739–1747, 2014. 2012.
249. Cichon S, Martin L, Hennies HC, et al: Increased activity of coagulation factor XII 282. Li W, Zheng X, Gu JM, , et al: Extraembryonic expression of EPCR is essential for
(Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098– embryonic viability. Blood 106:2716–2722, 2005.
1104, 2006. 283. Mohan Rao LV, Esmon CT, Pendurthi UR: Endothelial cell protein C receptor: A mul-
250. Cool DE, MacGillivray RT: Characterization of the human blood coagulation factor XII tiliganded and multifunctional receptor. Blood 124:1553–1562, 2014.
gene. Intron/exon gene organization and analysis of the 5′-flanking region. J Biol Chem 284. Wu C, Dwivedi DJ, Pepler L, et al: Targeted gene sequencing identifies variants in the
262:13662–13673, 1987. protein C and endothelial protein C receptor genes in patients with unprovoked venous
251. Johnson CY, Tuite A, Morange PE, et al: The factor XII -4C>T variant and risk of com- thromboembolism. Arterioscler Thromb Vasc Biol 33:2674–2681, 2013.
mon thrombotic disorders: A HuGE review and meta-analysis of evidence from obser- 285. Collen D, Tytgat GN, Claeys H, Piessens R: Metabolism and distribution of fibrinogen.
vational studies. Am J Epidemiol 173:136–144, 2011. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 22:681–
252. Morrissey JH, Gregory SA, Mackman N, Edgington TS: Tissue factor regulation and 700, 1972.
gene organization. Oxf Surv Eukaryot Genes 6:67–84, 1989. 286. Handagama PJ, Shuman MA, Bainton DF: In vivo defibrination results in markedly
253. Hoffman M, Colina CM, McDonald AG, et al: Tissue factor around dermal vessels has decreased amounts of fibrinogen in rat megakaryocytes and platelets. Am J Pathol
bound factor VII in the absence of injury. J Thromb Haemost 5:1403–1408, 2007. 137:1393–1399, 1990.
254. Banner DW, D’Arcy A, Chene C, et al: The crystal structure of the complex of blood 287. Louache F, Debili N, Cramer E, et al: Fibrinogen is not synthesized by human megakary-
coagulation factor VIIa with soluble tissue factor. Nature 380:41–46, 1996. ocytes. Blood 77:311–316, 1991.
255. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH: New fundamentals in hemostasis. 288. Côté HC, Lord ST, Pratt KP: gamma-Chain dysfibrinogenemias: Molecular structure-
Physiol Rev 93:327–358, 2013. function relationships of naturally occurring mutations in the gamma chain of human
256. Dorfleutner A, Ruf W: Regulation of tissue factor cytoplasmic domain phosphorylation fibrinogen. Blood 92:2195–2212, 1998.
by palmitoylation. Blood 102:3998–4005, 2003. 289. Henschen AH: Human fibrinogen—Structural variants and functional sites. Thromb
257. van den Hengel LG, Kocaturk B, Reitsma PH, et al: Complete abolishment of coagulant Haemost 70:42–47, 1993.
activity in monomeric disulfide-deficient tissue factor. Blood 118:3446–3448, 2011. 290. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, et al: Genetic variation in
258. Rehemtulla A, Ruf W, Edgington TS: The integrity of the cysteine 186-cysteine 209 the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing
bond of the second disulfide loop of tissue factor is required for binding of factor VII. J plasma fibrinogen gamma’ levels. Blood 106:4176–4183, 2005.
Biol Chem 266:10294–10299, 1991. 291. Blomback B: Studies on fibrinogen: Its purification and conversion into fibrin. Acta
259. Bogdanov VY, Balasubramanian V, Hathcock J, et al: Alternatively spliced human tissue Physiol Scand Suppl 43:1–51, 1958.
factor: A circulating, soluble, thrombogenic protein. Nat Med 9:458–462, 2003. 292. Olexa SA, Budzynski AZ: Evidence for four different polymerization sites involved in
260. Szotowski B, Antoniak S, Poller W, et al: Procoagulant soluble tissue factor is released human fibrin formation. Proc Natl Acad Sci U S A 77:1374–1378, 1980.
from endothelial cells in response to inflammatory cytokines. Circ Res 96:1233–1239, 293. Kaczmarek E, McDonagh J: Thrombin binding to the A alpha-, B beta-, and gam-
2005. ma-chains of fibrinogen and to their remnants contained in fragment E. J Biol Chem
261. Szotowski B, Goldin-Lang P, Antoniak S, et al: Alterations in myocardial tissue fac- 263:13896–13900, 1988.
tor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol 294. Weisel JW, Phillips GN Jr, Cohen C: The structure of fibrinogen and fibrin: II. Architec-
45:1081–1089, 2005. ture of the fibrin clot. Ann N Y Acad Sci 408:367–379, 1983.
262. Goldin-Lang P, Tran QV, Fichtner I, et al: Tissue factor expression pattern in human 295. Hantgan R, Fowler W, Erickson H, Hermans J: Fibrin assembly: A comparison of elec-
non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor tron microscopic and light scattering results. Thromb Haemost 44:119–124, 1980.
metastasis. Oncol Rep 20:123–128, 2008. 296. Marder VJ, Budzynski AZ: The structure of the fibrinogen degradation products. Prog
263. Luyendyk JP, Tilley RE, Mackman N: Genetic susceptibility to thrombosis. Curr Athero- Hemost Thromb 2:141–174, 1974.
scler Rep 8:193–197, 2006. 297. Mosesson MW: Update on antithrombin I (fibrin). Thromb Haemost 98:105–108, 2007.
264. Esmon NL, Owen WG, Esmon CT: Isolation of a membrane-bound cofactor for 298. Komaromi I, Bagoly Z, Muszbek L: Factor XIII: Novel structural and functional aspects.
thrombin-catalyzed activation of protein C. J Biol Chem 257:859–864, 1982. J Thromb Haemost 9:9–20, 2011.
265. Esmon CT, Owen WG: The discovery of thrombomodulin. J Thromb Haemost 2:209– 299. Souri M, Koseki-Kuno S, Takeda N, et al: Administration of factor XIII B subunit
213, 2004. increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.
266. Conway EM: Thrombomodulin and its role in inflammation. Semin Immunopathol Int J Hematol 87:60–68, 2008.
34:107–125, 2012. 300. Muszbek L, Haramura G, Polgar J: Transformation of cellular factor XIII into an
267. Light DR, Glaser CB, Betts M, et al: The interaction of thrombomodulin with Ca2+. Eur active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost
J Biochem 262:522–533, 1999. 73:702–705, 1995.
268. Adams TE, Huntington JA: Thrombin-cofactor interactions: Structural insights into 301. Brummel KE, Paradis SG, Butenas S, Mann KG: Thrombin functions during tissue fac-
regulatory mechanisms. Arterioscler Thromb Vasc Biol 26:1738–1745, 2006. tor-induced blood coagulation. Blood 100:148–152, 2002.
269. Cadroy Y, Diquelou A, Dupouy D, et al: The thrombomodulin/protein C/protein S anti- 302. Bagoly Z, Fazakas F, Komaromi I, et al: Cleavage of factor XIII by human neutrophil
coagulant pathway modulates the thrombogenic properties of the normal resting and elastase results in a novel active truncated form of factor XIII A subunit. Thromb Hae-
stimulated endothelium. Arterioscler Thromb Vasc Biol 17:520–527, 1997. most 99:668–674, 2008.
270. Laszik Z, Mitro A, Taylor FB Jr, et al: Human protein C receptor is present primarily 303. Smith KA, Pease RJ, Avery CA, et al: The activation peptide cleft exposed by thrombin
on endothelium of large blood vessels: Implications for the control of the protein C cleavage of FXIII-A(2) contains a recognition site for the fibrinogen alpha chain. Blood
pathway. Circulation 96:3633–3640, 1997. 121:2117–2126, 2013.
271. Lafay M, Laguna R, Le Bonniec BF, et al: Thrombomodulin modulates the mitogenic 304. Fraser SR, Booth NA, Mutch NJ: The antifibrinolytic function of factor XIII is exclu-
response to thrombin of human umbilical vein endothelial cells. Thromb Haemost sively expressed through alpha(2)-antiplasmin cross-linking. Blood 117:6371–6374,
79:848–852, 1998. 2011.
272. Van de Wouwer M, Conway EM: Novel functions of thrombomodulin in inflammation. 305. Aleman MM, Byrnes JR, Wang JG, et al: Factor XIII activity mediates red blood cell
Crit Care Med 32(Suppl 5):S254–S261, 2004. retention in venous thrombi. J Clin Invest 124:3590–3600, 2014.

Kaushansky_chapter 113_p1915-1948.indd 1946 9/21/15 2:41 PM